Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma

European Journal of Clinical Pharmacology

Volumn 71, Issue 12, 2015, Pages 1477-1484

  Diekstra, Meta H M ^a,b   Liu, Xiaoyan ^a,b,c   Swen, Jesse J ^a,b   Boven, Epie ^b,d   Castellano, Daniel ^e,f   Gelderblom, Hans ^a,b   Mathijssen, Ron H J ^b,g   Rodríguez Antona, Cristina ^h,i   García Donas, Jesus ^f,j   Rini, Brian I ^k   Guchelaar, Henk Jan ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Dutch SUTOX Consortium   (Netherlands)

^c SHANDONG UNIVERSITY   (China)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^f Spanish Oncology Genitourinary Group ^*  (Spain)

^g ERASMUS MC CANCER INSTITUTE   (Netherlands)

^h Structural Biology and Biocomputing Programme   (Spain)

ⁱ CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^j Clara Campal Comprehensive Cancer Center   (Spain)

^k TAUSSIG CANCER INSTITUTE   (United States)

more..

Author keywords

Metastatic renal cell carcinoma; Progression free survival; Single nucleotide polymorphism; Sunitinib; Toxicity; Tyrosine kinase inhibitor

Indexed keywords

CYTOCHROME P450 3A4; INTERLEUKIN 13; INTERLEUKIN 8; SUNITINIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; ALLELE; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CYP3A4 GENE; DRUG INDUCED DISEASE; EXPLORATORY RESEARCH; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HAND FOOT SYNDROME; HIF1A GENE; HUMAN; HYPERTENSION; IL13 GENE; IL4 R GENE; IL8 GENE; KIDNEY METASTASIS; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MET GENE; MUCOSA INFLAMMATION; NR1I2 GENE; OVERALL SURVIVAL; PATIENT HISTORY OF NEPHRECTOMY; POR GENE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; AGED; CARCINOMA, RENAL CELL; DISEASE FREE SURVIVAL; GENETICS; KIDNEY NEOPLASMS; METASTASIS; MIDDLE AGED; PATHOLOGY; STATISTICAL MODEL; SURVIVAL RATE;

AGED; ALLELES; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDOLES; INTERLEUKIN-13; INTERLEUKIN-8; KIDNEY NEOPLASMS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRROLES; SURVIVAL RATE;

EID: 84947021554     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-015-1935-7     Document Type: Article

References (36)

1. Motzer RJ, Rini BI, Bukowski RM et al (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295:2516-2524
2. Motzer RJ, Hutson TE, Cella D et al (2013) Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369:722-731
3. Shibata SI, Chung V, Synold TW et al (2013) Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res 19:3631-3639
4. Houk BE, Bello CL, Kang D, Amantea M (2009) A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res 15:2497-2506
5. van Erp NP, Eechoute K, van der Veldt AA et al (2009) Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol 27:4406-4412
6. van der Veldt AA, Eechoute K, Gelderblom H et al (2011) Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res 17:620-629
7. Garcia-Donas J, Esteban E, Leandro-García LJ et al (2011) Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol 12:1143-1150
8. Eechoute K, van der Veldt AA, Oosting S et al (2012) Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension. Clin Pharmacol Ther 92:503-510
9. Kim JJ, Vaziri SA, Rini BI et al (2010) Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. Cancer 118:1946-1954
10. Beuselinck B, Karadimou A, Lambrechts D et al (2013) Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib. Br J Cancer 108:887-900
11. Beuselinck B, Karadimou A, Lambrechts D et al (2014) VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis. Acta Oncol 53:103-112
12. Diekstra MH, Swen JJ, Boven E et al (2015) CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma. Eur Urol 68:621-629
13. Elens L, Bouamar R, Hesselink DA et al (2011) A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem 57:1574-1583
14. Elens L, van Gelder T, Hesselink DA et al (2013) CYP3A4∗22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. Pharmacogenomics 14:47-62
15. Diekstra MH, Klümpen HJ, Lolkema MP et al (2014) Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662. Clin Pharmacol Ther 96:81-89
16. Xu CF, Bing NX, Ball HA et al (2011) Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. J Clin Oncol 29:2557-2564
17. De Jonge H, Metalidis C, Naesens M et al (2011) The P450 oxidoreductase∗28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients. Pharmacogenomics 12:1281-1291
18. Oneda B, Crettol S, Jaquenoud Sirot E et al (2009) The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test. Pharmacogenet Genomics 19:877-883
19. Chu H, Wang M, Yan F et al (2012) Polymorphisms in the IL13 and IL-4R genes are associated with the development of renal cell carcinoma. Ann Oncol 23:2114-2121
20. Schutz FA, Pomerantz MM, Gray KP et al (2013) Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. Lancet Oncol 14:81-87
21. Kumar R, Crouthamel MC, Rominger DH et al (2009) Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer 101:1717-1723
22. Heng D, Xie W, Regan M et al (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27:5794-5799
23. Sherry ST, Ward MH, Kholodov M et al (2001) National Center for Biotechnology Information (NCBI) SNP database: the NCBI database of genetic variation. Nucleic Acids Res 29:308-311. Available from URL: http://www.ncbi.nlm.nih.gov/snp/
24. Lankhorst S, Kappers M, van Esch J et al (2014) Hypertension during vascular endothelial growth factor inhibition: focus on nitric oxide, endothelin-1, and oxidative stress. Antioxid Redox Signal 20:135-145
25. Petreaca ML, Yao M, Liu Y et al (2007) Transactivation of vascular endothelial growth factor receptor-2 by interleukin-8 (IL8/CXCL8) is required for IL8/CXCL8-induced endothelial permeability. Mol Biol Cell 18:5014-5023
26. Martin D, Galisteo R, Gutkind JS (2009) CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) Complex. J Biol Chem 284:6038-6042
27. Hacking D, Knight JC, Rockett K et al (2004) Increased in vivo transcription of an IL8 haplotype associated with respiratory syncytial virus disease susceptibility. Genes Immun 5:274-282
28. Amaya MP, Criado L, Blanco B et al (2013) Polymorphisms of pro-inflammatory cytokine genes and the risk for acute suppurative or chronic nonsuppurative apical periodontitis in a Colombian population. Int Endod J 46:71-78
29. Rini BI, Cohen DP, Lu DR et al (2011) Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 103:763-773
30. Xu CF, Johnson T, Garcia-Donas J et al (2015) IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma. Br J Cancer 112:1190-1198
31. Huang Y, Chen X, Dikov MM et al (2007) Distinct of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood 110:624-631
32. Shen R, Ye Y, Chen L et al (2008) Precancerous stem cells can serve as tumor vasculogenic progenitors. PLoS One 3, e1652
33. van der Pouw Kraan TC, van Veen A, Boeije LC et al (1999) An IL13 promoter polymorphism associated with increased risk of allergic asthma. Genes Immun 1:61-65
34. Tran HT, Liu Y, Zurita AJ et al (2012) Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol 13:827-837
35. Harmon CS, DePrimo SE, Figlin RA et al (2014) Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma. Cancer Chemother Pharmacol 73:151-161
36. Huang D, Ding Y, Zhou M et al (2010) Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 70:1063-1071